Slide 1: Corporate Overview
Corporate Overview All Employee Meeting at Trubion's Corporate HQ PLEASE NOTE: ALL TITLE SLIDES BASED ON A TITLE MASTER IN AUTO LAYOUT DATE AUTOMATIC TO TURN OFF: [View>Header and Footer...] On Slide tab, uncheck Date and Time, then click Apply
Slide 2: Forward-Looking Statements / Note on Guidance
This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, proj
Slide 3: Clear Business Focus
Market Focus Infectious disease market Unmet medical needs & underserved global markets Product Focus Immune-related biologics (e.g., vaccines & antibody therapies) Disease Focus Anthrax Tuberculosis Typhoid Universal Flu Chlamydia Customer Focus Government Private Sector Corporate Overview Clear Bu
Slide 4: Successful Track Record of Acquisitions and Delivering Results
Microscience Ltd (UK) acquired Antex Biologics (US) acquired Michigan Biologics Products Institute assets acquired Lansing facility renovation approved by FDA ViVacs GmbH (Germany) acquired 1998 IPO and NYSE listing completed 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Joint venture
Slide 5: Broad Product Portfolio (targeting Infectious Diseases)
Product Preclinical Phase I Phase II Phase III Marketed BioThrax(r) (Anthrax Vaccine Adsorbed) Tuberculosis Vaccine (MVA85A) Clinical Anthrax Immune Globulin (AIG) Parallel studies1 Licensed TyphellaTM (Typhoid Vaccine Live Oral ZH9) Recombinant Anthrax Vaccine (rPA) Universal Flu Vaccine 1 A critic
Slide 6: 2010 Key Corporate Milestones
Type of Contract Funding Agency Description Term Expected Timing Potential Total Contract Amount Development BARDA Large-scale Manufacturing Process for BioThrax(r) (Building 55) Multi Year Announced 07/13/10 $107M Development BARDA rPA Development Multi Year End of 3Q >$200M Procurement CDC/HHS Dos
Slide 7: Recent Announcement - 2Q / 6 Month 2010 Financial Performance
Total Revenues -- $62.1M $108.9M Net Income -- $9.8M $12.3M EPS -- $0.32 $0.40 Cash Balance -- $102.9M* * Excluding accounts receivable of $45.8M Corporate Overview Recent Announcement - 2Q / 6 Month 2010 Financial Performance 2Q10 6M10
Slide 8: Continued Revenue Growth and Profitability
2005 2006 2007 2008 2009 2010P Total 131 153 182.915 178.718 234.786 275 25 $131 $153 $183 $234 $179 $300 to $275 Total Revenue ($ millions) 2005 2006 2007 2008 2009 2010P Total 16 23 23 21 31 40 10 $16 $23 $23 $31 $21 $50 to $40 Net Income ($ millions) Corporate Overview Continued Revenue Growth an
Slide 9: Continuing History of Delivery Under USG Contracts
Signed Doses Contract Value Contract Term Delivery Status September 2004 5M $124M September 2004 to September 2007 Completed May 2005 5M $120M May 2005 to May 2006 Completed May 2006 5M $123M May 2006 to May 2007 Completed September 2007 18.75M $448M September 2007 to September 2010 Completed Octobe
Slide 10: Extensive USG and NGO Funding for R&D Pipeline
Product Partner $ (millions) BioThrax(r) dual adjuvant NIAID/BARDA 30 AIG NIAID 13 Anthrax MAb NIAID/BARDA 24 rPA NIAID/BARDA 1001 Typhoid Vaccine (TyphellaTM) Wellcome Trust (UK) 2 TB Vaccine (MVA85A) Wellcome Trust (UK) / AERAS (US) 16 TOTAL TOTAL $185 TB Chlamydia Flu Typhoid Anthrax 1 Reflects f
Slide 11: Expanding Lansing Manufacturing Capacity
2010P 2011P 2012P 2013P 2014P Building 12 7 7.5 8 7 Building 55 0 0 0 18 25 7.0 7.5 25.0 Building 12 Building 551 1 Assumes one 1320L fermentation train; second fermentation train for surge requirement Total Capacity (millions) 8.0 25.0 Expanding Lansing Manufacturing Capacity Corporate Overview
Slide 12: Manufacturing Capability for R&D Pipeline
Anthrax TB Typhoid Flu Chlamydia Baltimore Facility Baltimore Facility Baltimore Facility Facility Size 56,000 sq. ft. Including 11,000 sq. ft. for manufacturing 56,000 sq. ft. Including 11,000 sq. ft. for manufacturing Production Configuration Multiple segregated production suites Concurrent manufa
Slide 13: Company Highlights
Near term growth from licensed vaccine BioThrax(r) Medium term growth from high value R&D pipeline Longstanding financial strength Corporate Overview Company Highlights
Slide 14: Corporate Overview
Corporate Overview All Employee Meeting at Trubion's Corporate HQ PLEASE NOTE: ALL TITLE SLIDES BASED ON A TITLE MASTER IN AUTO LAYOUT DATE AUTOMATIC TO TURN OFF: [View>Header and Footer...] On Slide tab, uncheck Date and Time, then click Apply